This announcement contains inside information
13 July 2016 07:00
ASTRAZENECA ENTERS INTO AGREEMENT TO RESOLVE FASLODEX PATENT LITIGATION IN THE
US
AstraZeneca today announced that it has entered into an agreement with Sandoz,
Inc. and affiliates ("Sandoz") to resolve Faslodex (fulvestrant) patent
litigation in the US relating to Sandoz's generic fulvestrant product, for which
it is seeking FDA approval.
The US Faslodex patents in question are due to expire in January 2021, with
paediatric exclusivity continuing until July 2021. On 12 July 2016, the United
States District Court for the District of New Jersey entered a consent judgment
filed by AstraZeneca and Sandoz, which includes an injunction preventing Sandoz
from launching a generic fulvestrant product until 25 March 2019, or earlier in
some circumstances.
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on
the discovery, development and commercialisation of prescription medicines,
primarily for the treatment of diseases in three therapy areas - Respiratory and
Autoimmunity, Cardiovascular and Metabolic Diseases, and Oncology. The Company
is also active in inflammation, infection and neuroscience through numerous
collaborations. AstraZeneca operates in over 100 countries and its innovative
medicines are used by millions of patients worldwide. For more information
please visit: www.astrazeneca.com
CONTACTS
+-------------------+-------------------------------------+----------------+
|Media Enquiries | | |
+-------------------+-------------------------------------+----------------+
|Neil Burrows |UK/Global |+44 7824 350541 |
+-------------------+-------------------------------------+----------------+
|Vanessa Rhodes |UK/Global |+44 7880 400690 |
+-------------------+-------------------------------------+----------------+
|Karen Birmingham |UK/Global |+44 7818 524012 |
+-------------------+-------------------------------------+----------------+
|Rob Skelding |UK/Global |+44 7392 103298 |
+-------------------+-------------------------------------+----------------+
|Jacob Lund |Sweden |+46 8 553 260 20|
+-------------------+-------------------------------------+----------------+
|Michele Meixell |US |+1 302 885 2677 |
+-------------------+-------------------------------------+----------------+
|Investor Relations | | |
+-------------------+-------------------------------------+----------------+
|UK | | |
+-------------------+-------------------------------------+----------------+
|Thomas Kudsk Larsen| |+44 7818 524185 |
+-------------------+-------------------------------------+----------------+
|Nick Stone |Respiratory and Autoimmunity |+44 7717 618834 |
+-------------------+-------------------------------------+----------------+
|Henry Wheeler |Oncology |+44 7788 354619 |
+-------------------+-------------------------------------+----------------+
|Craig Marks |Finance, Fixed Income, M&A |+44 7881 615764 |
+-------------------+-------------------------------------+----------------+
|Christer Gruvris |Infection and Neuroscience |+44 7827 836825 |
+-------------------+-------------------------------------+----------------+
|US | | |
+-------------------+-------------------------------------+----------------+
|Lindsey Trickett |Cardiovascular and Metabolic Diseases|+1 240 543 7970 |
+-------------------+-------------------------------------+----------------+
|Mitchell Chan |Oncology |+1 240 477 3771 |
+-------------------+-------------------------------------+----------------+
|Toll-free | |+1 866 381 7277 |
+-------------------+-------------------------------------+----------------+
Adrian Kemp
Company Secretary
AstraZeneca PLC
-ENDS-
AZ resolves Faslodex patent litigation in the US
| Source: AstraZeneca PLC